Navigation Links
Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
Date:9/3/2008

SYDNEY, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

The Phase 3 trial is being conducted in 41 hospitals across North America, Argentina and Germany, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the United States.

Pharmaxis Chief Executive Officer Dr Alan Robertson said: "We are delighted to commence this trial following helpful discussions with the FDA and with assistance from the U.S. Cystic Fibrosis Foundation. This trial follows the recent closure to recruitment of the first Phase 3 trial involving 325 subjects. Bronchitol has been awarded fast-track status in the U.S., and orphan drug designation in both the U.S. and EU and we look forward to bringing Bronchitol to the international cystic fibrosis community as rapidly as we can."

This trial is being conducted under the Food and Drug Administration's Special Protocol Assessment (SPA) scheme. The SPA process ensures the clinical trial protocol is acceptable to the U.S. FDA when the results are submitted to support a marketing application for Bronchitol.

The Phase III clinical trial is designed to include a 26-week efficacy treatment period, followed by a 26-week safety period. The efficacy component of the trial is a randomized, double-blind investigation of Bronchitol twice daily in approximately 300 patients with cystic fibrosis. The trial is enrolling cystic fibrosis patients aged six years and older. Participants will be assessed for improvements in lung function, infectious episodes, antibiotic use, quality of life and a range of health economic measures. Further details concerning the trial are available at

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
2. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
3. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
4. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... results for the third quarter fiscal year 2015 ... scheduled a conference call that same day, Thursday, ...
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
(Date:4/30/2015)... 2015 Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its first quarter ... for the first quarter of 2015 was $116.2 million, ... of 2014, and down $5.3 million or 4.4% from ... 2015 net income as reported in accordance with U.S. ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27
... Mont., Feb. 1, 2012 Bacterin International Holdings ... leader in the development of revolutionary bone graft material ... Hayden IR , a 15-year-old, highly recognized, national investor ... relations program and raise its visibility and strengthen its ...
... 1, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Food and Drug Administration (FDA) has notified Arena that ... discuss the lorcaserin New Drug Application (NDA) resubmission will ... and details of the meeting will be published in ...
Cached Medicine Technology:Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 2Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 3Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 4Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 2Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 3Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 4
(Date:5/3/2015)... 2015 Indiana Fiber Network, LLC (IFN), ... Computer Services, Inc (BCS) has selected IFN as a ... “The technology, service, and working relationship with IFN has ... local feel you get with IFN. I like ... makes local decisions and operates as a local community ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 SpineFrontier, a ... from the FDA to produce and market their new ... can be used in outpatient settings and is compatible ... alternate posterior approach has been extensively researched and refined ... approval to use this approach in conjunction with a ...
(Date:5/2/2015)... May 02, 2015 Ticket Down has secured ... for the long awaited event today, Saturday, May 2nd at ... boxing fans will be able to secure tickets for both ... fight that boxing fans have wanted for more than five ... Floyd “Money” Mayweather will step inside the ring to fight ...
(Date:5/2/2015)... New York, NY (PRWEB) May 02, 2015 ... – when a deadly natural disaster strikes anywhere on ... ways to leverage human sympathy and compassion for their ... US-CERT (United States Computer Emergency Readiness Team) issued ... warning users “of potential email scams citing the earthquake ...
(Date:5/2/2015)... 02, 2015 Kare Visits LLC. launched in ... busy caregivers. Kare Visits offers relief for caregivers by ... facilities. According to the Caregiver Action Network, eight ... of 20 hours a week caring for an elderly or ... to hire a nurse, a caregiver is now empowered to ...
Breaking Medicine News(10 mins):Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... 3 Health Care Service Corporation (HCSC),which operates the ... Oklahoma and Texas, today announced that its board of ... chief executive officer,effective Nov. 1, 2008., Hemingway Hall, ... since November 2007, will succeed Raymond F. McCaskey, who ...
... emergency physicians access to earn CME ... credit for watching online video procedures, NEW ... leading global provider of information resources for the,scientific and ... the largest membership organization for emergency,physicians, to launch Continuing ...
... Educational resources and special product offers available in store during ... American Diabetes Month ... retail pharmacy, is educating patients about managing and,preventing diabetes during ... during the month on products for patients,with diabetes., Nearly ...
... is available in German . , SARS, ... becoming increasingly frequent. And we still don,t have vaccines for ... classes of viral diseases is the zoonosis, which can be ... of these is caused by the West Nile virus (WNV), ...
... have found that reducing the levels of vascular endothelial growth ... new blood vessel growth, in adult mice causes the death ... that are essential to visual function. This finding, published in ... for the chronic use of promising new anti-VEGF drugs such ...
... Program; Inaugural Partner for ... Fund(R), LONDON, Nov. 3 Susan G. ... organization in the world, is teaming with,Samsung Electronics ... in Europe, in a collaboration unparalleled in the ...
Cached Medicine News:Health News:Hemingway Hall Named CEO of Health Care Service Corporation 2Health News:McGraw-Hill Professional and American College of Emergency Physicians Roll Out CME Functionality On AccessEmergency Medicine 2Health News:McGraw-Hill Professional and American College of Emergency Physicians Roll Out CME Functionality On AccessEmergency Medicine 3Health News:CVS/pharmacy Helps Patients Manage Diabetes Care 2Health News:Therapeutic vaccines 2Health News:Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution 2Health News:Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution 3Health News:Samsung and Susan G. Komen for the Cure(R) Launch Historic Breast Cancer Alliance 2Health News:Samsung and Susan G. Komen for the Cure(R) Launch Historic Breast Cancer Alliance 3
... instrument engineered to match the speed of ... system is based on heat transfer by ... tubes or thin walled micorcentrifuge tubes. Heating ... high velocity air results in nearly instantaneous ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... Biosystems has designed its 60-well, 0.5 mL ... PCR applications (both DNA and RNA). The ... Frame ensure oil-free operation in the 0.5 ... the 0.5 mL GeneAmp PCR System 9700 ...
... Mx3005P instrument and custom filter wheels ... filters. The standard filter set includes: ... ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) and ... Mx3005P analysis software, Beacon Designer oligo ...
Medicine Products: